Amicus Therapeutics
Sustainability Report and Carbon Intensity Rankings
Is Amicus Therapeutics doing their part?
Their DitchCarbon score is 43
Amicus Therapeutics has a DitchCarbon Score of 43 out of 100, indicating moderate performance in sustainability practices. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to lower carbon intensity would enhance Amicus Therapeutics’ sustainability profile.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Amicus Therapeutics is part of the finance sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Amicus Therapeutics is situated in the United States, which has a low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.
Unlock 30+ emissions data points on Amicus Therapeutics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Amicus Therapeutics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
7.83%
...this company is doing 7.83% worse in emissions than the industry average.
Amicus Therapeutics, founded in 2002 and headquartered in Cranbury, operates within the biotechnology industry, focusing on rare and orphan diseases. The company is dedicated to developing advanced therapies for conditions such as Fabry disease, Pompe disease, and Epidermolysis Bullosa. Amicus Therapeutics prioritizes the needs of the rare disease community, aiming to significantly impact patients’ lives through their innovative science and clinical programs.
Bad news, Amicus Therapeutics hasn't committed to SBTi goals yet
Amicus Therapeutics has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not formally defined or announced targets for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.